Day: August 26, 2021

Acuant will provide KYC and Identity Verification tech for seamless, compliant financial solutions

LOS ANGELES, Aug. 26, 2021 (GLOBE NEWSWIRE) — Acuant, the leading global Trusted Identity Platform for fraud prevention and AML compliance, today announced a new partnership with Finaptic, Canada’s only end-to-end, white-label Banking-as-a-Service (BaaS) provider. As the company quickly expands, Finaptic will leverage Acuant’s fully automated technology for Onboarding with Know Your Customer (KYC) and Document Verification to meet Anti-Money Laundering (AML) regulation and compliance standards.

Finaptic is a leading end-to-end banking-as-a-service (BaaS) provider that combines the power of a traditional banking platform with the flexibility of a modern technology stack to create better customer experiences. Located in Canada, Finaptic’s platform allows companies across all major industries to easily offer value-added, fully compliant banking products to their customers and build brand loyalty. Real time, event-driven technology allows its partners to embed a full-range of banking products into their own branded user experiences.

“At Finaptic, our purpose-built platform incorporates cybersecurity, regulatory compliance and data privacy by design, bringing the trust and security which Canadians expect in banking. Our modern, flexible platform is designed to deliver the next generation of banking experiences through the client’s preferred distribution point,” said David Furlong, co-founder and CEO of Finaptic. “We are very pleased to announce this partnership with Acuant; leveraging Acuant’s technology allows us to securely onboard clients remotely while seamlessly meeting compliance needs.”

To provide Finaptic’s partners the most trusted customer experience, Acuant is collaborating with Finaptic to provide its best-of-breed technologies customized to their use case and level of risk. Finaptic is leveraging Acuant’s fully automated KYC and Identity Verification for fast, secure and robust identity proofing.

“We are excited to partner with Finaptic and provide exactly what they are looking for,” said Yossi Zekri, President and CEO at Acuant. “They value the strength of our platform and that they are able to customize solutions to meet their individual use cases, all while being managed via a single API and a single contract. We look forward to their continued growth and success as their trusted partner.”

About Acuant
Acuant’s Trusted Identity Platform is at the forefront of empowering businesses and governments to transact with trust in an ever-increasing digital world. Enabling the creation, ownership and ability to verify and securely share a digital identity, Acuant’s inclusive technology is accessible to the entire global population.

AI-powered, industry leading identity verification, regulatory compliance (AML/KYC) and digital identity solutions deliver unparalleled results and operational efficiency with omnichannel deployment. Acuant verifies identities in seconds anywhere your customers want to transact, providing superior customer experiences to fight fraud and fast-track trusted identities.

Completing more than 1.5 billion transactions in over 200 countries and territories, Acuant powers trust globally for industry leaders in finance, crypto, retail, healthcare, gaming, hospitality and more.

Acuant Media Contact
Malini Gujral
marketing@acuant.com

Finaptic Media Contact
press@finaptic.com

A video accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2cf1d462-0399-4209-ae96-7ba9ac9228c3

August 26, 2021 

• Company’s innovative, integrated imaging systems, devices, software, informatics and services support greater efficiency, enabling high-quality care for a growing volume of complex cardiac patients
• Early detection, accurate diagnosis, precise treatment and easy follow-up are enabled by data-driven, streamlined workflows

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of its digital experience during the virtual European Society of Cardiology (ESC) 2021 Congress, taking place August 27-30, during which it will showcase its latest suite of solutions to help improve outcomes for patients with cardiovascular disease by enabling quick, confident diagnoses, and efficient, effective treatments. During the congress, Philips will demonstrate its continued leadership in cardiology across its integrated portfolio of solutions throughout the entire cardiac care journey, from early detection, diagnosis and treatment, to long-term follow-up.

Cardiovascular disease has become the number one healthcare challenge globally and is one of the leading causes of death worldwide [1]. The costs associated with cardiovascular diseases are rising significantly, with an expected growth in cost of 101% by 2035 [2]. The demands on cardiology departments are higher than ever before, forcing clinicians to balance the delivery of high-quality care for a growing volume of complex patients, while dealing with the pressures to improve departmental efficiency at the same time. Definitive diagnostics, innovative procedures and personalized patient management are essential to help address these most challenging demands.

“From emergency care to diagnosis and treatment, to care into the home, cardiac care teams need the right information and support available at their fingertips across the entire cardiac patient journey,” said Bert van Meurs, Chief Business Leader of Image Guided Therapy at Philips. “Philips is uniquely positioned to integrate imaging, devices, software, informatics and services at each point in a cardiac patient’s journey to help deliver results now, while positioning for future success. At this year’s ESC virtual congress, we continue our longstanding leadership in cardiology, as we demonstrate the latest smart solutions to help improve the precision diagnosis and effective treatment for patients in cardiac care, driving better outcomes and lower cost while improving the patient and staff experience.”

Philips cardiology experience at the Virtual ESC 2021 Congress
Visitors to the Philips virtual experience during ESC will see how Philips’ solutions help strengthen clinical confidence with robust data and advanced technologies to give insight to provide the right care at the right time, improving outcomes for even the most complex patients. Building efficiency throughout the care pathway, Philips is streamlining communication between devices and systems to identify and address operational improvements to optimize resources and help reduce costs. By improving cardiac care experiences with user-friendly tools and streamlined workflows, Philips is helping relieve pain points for staff and enhancing comfort for patients.

Technology highlights in diagnostic and treatment solutions at this year’s virtual ESC congress include:

• Philips Spectral CT 7500 for advanced cardiac imaging. The new Philips Spectral CT 7500, designed to support diagnosis, builds on Philips’s strong reputation in cardiac imaging by delivering fast cardiac scans with excellent coronary vessel visualization, and now layers of spectral information for every exam. The spectral detector allows the Spectral CT 7500 to be the only system that will acquire spectral cardiac data in the same time and place for all patients, from pediatrics to bariatrics. This latest intelligent system has demonstrated a 34% reduction in time to diagnosis [3], a 25% reduction in repeat scans and a 30% reduction in follow-up scans [4] compared to conventional CT. The time-saving spectral workflow is fully integrated, enabling spectral chest scans. Intelligent workflows of Philips IntelliSpace Portal simplify advanced vessel analysis, comprehensive cardiac assessment, lung nodule assessment, and transcatheter aortic valve implantation (TAVI) to expand cardiac and ED trauma capabilities.
• New innovations in ultrasound enhance clinical efficiency and diagnostic confidence. Philips’ new echo imaging, quantification, and tele-health technologies help improve clinical confidence, automate repetitive tasks, and remotely and securely connect clinicians and patients. Philips brings together the EPIQ CVx and Affiniti CVx ultrasound platforms, TOMTEC advanced analysis, Collaboration Live remote decision support and Philips multi-modality image and information management solutions (IntelliSpace Cardiovascular) in an end-to-end workflow, for a fully integrated experience in echocardiography.
• Improved workflow and patient focus in image guided procedures. Philips will demonstrate the integration of its Interventional Hemodynamic System and market-leading portable Patient Monitor IntelliVue X3, providing advanced hemodynamic (blood flow) measurements at the tableside in the cath lab and continuous monitoring of key vital signs throughout the patient journey [5]. The integration provides the opportunity for monitoring during image-guided procedures on the Philips Image Guided Therapy System – Azurion, improving workflow with comprehensive patient records that support timely clinical decision-making during interventional cardiology procedures and beyond.
• Cardiology informatics solutions drive actionable insights to enhance cardiology care. Philips Cardiovascular Informatics solution provides a consistent end-to-end intuitive workflow for easy access to a patient’s cardiovascular pathway. By connecting and integrating disparate clinical systems across the enterprise, the cardiology care team can make fast clinical decisions based on the data when and where it is needed. Philips cardiology informatics solutions, smart intelligent algorithms and predictive analytics work seamlessly to help optimize patient throughput.

Advanced cardiac monitoring from the hospital into the home
Philips cardiac care solutions and BioTelemetry’s leading remote cardiac patient monitoring  have transformed the cardiac care pathway. Now, individuals with complex co-morbidities can emerge from a cardiac event or procedure to live independently with the confidence of 24/7 clinical oversight with advanced cardiac monitoring including monitoring of wearables and implantable devices for a complete end-to-end solution across acute and non-acute settings, from the hospital into the home.

Philips hosted webinars and symposia sessions during ESC 2021
ESC delegates can join Dr. Roberto Lang of the University of Chicago Medicine, along with Dr. Pepe Zamorano of the University Hospital Ramón y Cajal, Madrid, Spain and Dr. Eric Saloux with Coen University Hospital, France during an Ultrasound Satellite Symposia session on August 28 at 8:00AM CET, as they present results on new imaging technologies under investigation. ESC attendees can also join Dr. Tim Leiner, Professor of Radiology at Utrecht University Medical Center in the Netherlands, who will share the latest results and advantages of cardiovascular imaging with the next generation Spectral CT 7500.

On August 27 at 10:00AM CET, Dr. Borja Ibáñez, Director of Clinical Research of the National Center Cardiovascular Research (CNIC) in Spain will also be presenting results from ultra-fast cardiac MR scanning, reducing MRI evaluation of the heart to a few minutes. Visit the Philips ESC Engagement Hub for the full list of Philips hosted webinars throughout the event.

For more information, join the Philips virtual experience at ESC 2021. Visit www.philips.com/cardiology and the Philips Press Backgrounder for more information on Philips full suite of integrated imaging, devices, software, informatics and services enhancing precision heart care. And join @PhilipsLiveFrom to follow Philips for updates throughout the event.

[1] European Cardiovascular Disease Statistics 2017.
[2] RTI International for the American Heart Association. Projections of Cardiovascular Disease Prevalence and Costs: 2015–2035.
[3] Andersen, MB, Ebbesen, D, Thygesen, J, et al. impact of spectral body imaging in patients suspected for occult cancer: a prospective study of 503 patients. Eur Radiol (2020). Results from case studies are not predictive of results in other cases. Results in other cases may vary. https://doi.org/10.1007/s00330-020-06878-7.
[4] Analysis by CARTI Cancer Center in Little Rock Arkansas and University Hospitals of Cleveland. Results from case studies are not predictive of results in other cases. Results in other cases may vary.
[5] Philips Interventional Hemodynamic System with Patient Monitor IntelliVue X3 is available in the majority of markets worldwide. Philips’ continuous patient monitoring solution is available for sale in markets across Europe, Middle East and APAC, with further expansion planned later this year. It is not available for sale in the U.S.

For further information, please contact:

Mark Groves
Philips Global Press Office
Tel.: +31 631 639 916
E-mail: mark.groves@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 17.3 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

• Philips EPIQ CVx in use
• Philips Collaboration Live
• Philips Azurion in use
• Philips IntelliSpace Cardiovascular
• Philips Hemodynamic with IntelliVue X3

Heineken® unveils new UEFA and Motorsports partnerships
Bringing fans together over world-class sports

AMSTERDAM, Aug. 26, 2021 (GLOBE NEWSWIRE) — The hope, the cheers, the suspense, the celebration – and having the very best of times before, during and after a sports event… it’s what fans want, now more than ever. That’s why Heineken^® is announcing new partnerships to provide even more top performances for fans to cheer on with UEFA’s Women’s Champions League, UEFA Women’s EURO 2022 and 2025, and W Series, the international single-seater motor racing championship for female drivers.

Fans can look forward to world-class sport, accompanied by exclusive DJ sets to round off the action and emotion. For Heineken^® it’s a new chapter in its commitment to fans, building on thriving partnerships within football and motorsport.

Bram Westenbrink, Global Head Heineken^® Brand, said:

“We are committed to delivering great shared moments to consumers all over the world and our sponsorships are exciting platforms to connect with fans through their passions and enhance their experiences. By extending our partnerships in football and motorsport to include W Series, UEFA Women’s Champions League and UEFA Women’s EURO 2022 and 2025, we are enabling more thrilling experiences for all.”

Julia George, Global Sponsorship Manager for Heineken^®, said:

“Our multi-year deals with W Series, UEFA Women’s Champions League and UEFA Women’s EURO 2022 and 2025 enable us to create even more world-class experiences to enhance the sports that fans love. And we know that fan passion is not determined by gender, but by coming together over the love for the sport and the world class athletes. That’s why we are proud to announce extensions to our partnerships in football and motorsport.”

Nadine Kessler, Chief of Women’s Football at UEFA, said: “We are delighted to expand our fantastic 25-year relationship with Heineken^® through to the UEFA Women’s Champions League and UEFA Women’s EURO 2022 and 2025. This expansion demonstrates Heineken^®’s continued commitment to being an advocate and supporter of the whole of European football, women’s and men’s, and the amazing fans, players and coaches who make these tournaments so special.”

Catherine Bond-Muir, CEO of W Series, said: “This partnership marks another exciting step forward for W Series and our mission to further the interests and prospects of female racing drivers. Heineken^®’s commitment to supporting us shows how W Series is going from strength to strength enhancing the way our fans watch racing through exceptional experiences. We know the incredible support that Heineken^® brings through their outstanding engagement with racing fans across the world and we are delighted to partner with Heineken^® for this incredible journey.”

Heineken^®’s partnership with UEFA women’s tournament will extend through until the end of the 2024/25 season. The partnership will provide Heineken^® with additional ticketing, hospitality, branding and pouring opportunities as well as digital fan activations including the Heineken Goal of the Round, and in stadium activations and experiences for fans like the Heineken Best Seat in the House.

Heineken^®’s multi-year deal with W Series will give the premium beer brand at-track visibility at races, Heineken^® 0.0, digital activation ‘Heineken Star of the Track’, its continued support to responsibility through When You Drive Never Drink and – of course – track-side fan experiences throughout the season. 2021 is a big year for W Series, which launched in 2018. For the first time the championship will join eight Formula 1, Grand Prix races across the season, giving motorsport fans the opportunity to watch the world’s top female drivers compete.

The announcement of these new sponsorships is celebrated in a new film featuring Heineken^® ambassadors Thierry Henry and David Coulthard, alongside Pernille Harder, Melanie Leupolz, Jamie Chadwick, and Naomi Schiff. The film captures the shared magic, drama and excitement of sports – that is what makes it so special for the fans.

The short film can be viewed in full here: [link]

A Media Snippet accompanying this announcement is available by clicking on the image or link below:

Notes to Editors:

Press Enquiries: Archie Patch (Edelman) archie.patch@edelman.com /heinekenglobalpr@edelman.com

About HEINEKEN:

HEINEKEN is the world’s most international brewer. It is the leading developer and marketer of premium beer and cider brands. Led by the Heineken^® brand, the Group has a portfolio of more than 300 international, regional, local and specialty beers and ciders. We are committed to innovation, long-term brand investment, disciplined sales execution and focused cost management. Through “Brewing a Better World”, sustainability is embedded in the business.

HEINEKEN has a well-balanced geographic footprint with leadership positions in both developed and developing markets. We employ over 80,000 employees and operate breweries, malteries, cider plants and other production facilities in more than 70 countries. Heineken N.V. and Heineken Holding N.V. shares trade on the Euronext in Amsterdam. Prices for the ordinary shares may be accessed on Bloomberg under the symbols HEIA NA and HEIO NA and on Reuters under HEIN.AS and HEIO.AS. HEINEKEN has two sponsored level 1 American Depositary Receipt (ADR) programmes: Heineken N.V. (OTCQX: HEINY) and Heineken Holding N.V. (OTCQX: HKHHY).

Most recent information is available on HEINEKEN’s website: www.theHEINEKENcompany.com and follow us on Twitter via @HEINEKENCorp.

About W Series:

W Series is a free-to-enter championship, launched in October 2018, that provides equal opportunities for women.

W Series drivers are selected purely on their ability and the series’ cars are mechanically identical, which means that W Series races and championships will be won by the most talented drivers.

The more high-profile female role models it can create, the more W Series believes it will bring more females into the sport. Central to W Series’ mission is the idea that if you can see it, you can be it.

Le Castellet, Spielberg, Austria, Silverstone, UK, Budapest, Hungary, Spa-Francorchamps, Belgium, Zandvoort, Netherlands, Austin, USA, Mexico City, Mexico

For more information, including Championship Standings, visit W Series website: www.wseries.com

About UEFA Women’s Champions League:

A new UEFA Women’s Champions League format will be introduced from 2021/22, including a 16-team group stage as well as centralised marketing and TV coverage.

The change was agreed by the UEFA Executive Committee in Nyon as the first direct outcome of the UEFA women’s football strategy #TimeForAction, which aims to double the reach and value of the UEFA Women’s Champions League.

The change means a 20% increase in the number of matches, or a 39% increase excluding the first round which is played in the form of mini-tournaments, and gives the tournament more competitive games and increased visibility and quality. The new format was developed by UEFA in close collaboration with the clubs and the European Club Association and will set a new benchmark for an international women’s club football competition.

The 2021/2022 Final is set to be hosted in Turin.

For more information, including group standings and fixture lists, visit www.uefa.com/womenschampionsleague.com.

About UEFA Women’s EURO 2022:

UEFA Women’s EURO 2022 will be played from 6 to 31 July in England, across 9 stadiums, with 15 other nations joining the host country for the tournament.

The 16 sides will be drawn into four groups of four, with the top two in each section progressing to the knockout phase. . The draw for the group stages will take place on the 28^th of October 2021. The final will take place at Wembley Stadium on the 31^st of July 2022.

For more information, visit www.uefa.com/womenseuro/.

Paris, France and Tokyo, Japan – August 26, 2021 – Atos today announced that it has selected Daiwabo Information System (DIS), leading distributor of IT-related products in Japan, to distribute its cybersecurity products locally. This partnership between Atos and DIS represents Atos’ first cybersecurity distribution agreement in Japan and is an important step to expand Atos’ international channel strategy and partner ecosystem. This partnership will allow Japanese businesses and organizations embarking on digital transformation and cloud initiatives to protect their key data and assets with proven solutions.

As part of the partnership between Atos and DIS, Atos’ Evidian portfolio for identity and access management will be distributed through DIS’ network of 19,000 resellers across Japan.

“We are very pleased to be working with Atos and to bring its cybersecurity products to more customers in Japan – promoting secure solutions that are tailored to the needs of end customers. Cybersecurity is everyone’s business, and we see that Japanese organizations have well integrated the importance of the topic in their digital transformation approach,” comments Daiwabo Information System Purchasing department.

“We are delighted to sign a key cybersecurity product distribution agreement with Daiwabo Information System. This further strengthens our commitment to customers in Japan, expands our reach in Asia, and underlines our willingness to expand our network of strategic distributors globally.” says Alexis Caurette, Vice President, Head of cybersecurity products at Atos.

Atos is a global leader in cybersecurity with over 6000 security experts, a worldwide network of Security Operations Centers and a full range of cybersecurity products holding the highest certifications available on the market: https://atos.net/en/solutions/cyber-security-products

***

About Daiwabo Information System Co., Ltd.

As one of Japan’s leading distributors of IT-related products, DIS supplies such products, purchased from around 1,300 makers and suppliers, both at home and abroad, to end users across the country, through our network of around 19,000 dealers in Japan. Operating roughly 90 sales bases throughout the country, we have a well-established and community-based sales system, and can respond to a wide-range of requests from our customers, as a friendly and trustworthy distributor. https://www.pc-daiwabo.co.jp/english/

About Atos

Atos is a global leader in digital transformation with 105,000 employees and annual revenue of over € 11 billion. European number one in cybersecurity, cloud and high performance computing, the Group provides tailored end-to-end solutions for all industries in 71 countries. A pioneer in decarbonization services and products, Atos is committed to a secure and decarbonized digital for its clients. Atos operates under the brands Atos and Atos|Syntel. Atos is a SE (Societas Europaea), listed on the CAC40 Paris stock index.

The purpose of Atos is to help design the future of the information space. Its expertise and services support the development of knowledge, education and research in a multicultural approach and contribute to the development of scientific and technological excellence. Across the world, the Group enables its customers and employees, and members of societies at large to live, work and develop sustainably, in a safe and secure information space.

Atos press contact

Atos: Marilyn Florent – marilyn.florent@atos.net – +33 (0)6 65 06 20 07

Attachment

• News (Global) Atos offers Daiwabo Information System partners access to Atos cybersecurity products

เทเมคูลา, แคลิฟอร์เนีย, Aug. 26, 2021 (GLOBE NEWSWIRE) — Nikkiso Cryogenic Industries’ Clean Energy & Industrial Gases Group (Group) บริษัทในเครือ Nikkiso Co., Ltd (Japan) ยินดีที่จะประกาศว่า Etan Hon ได้รับแต่งตั้งให้เป็นผู้จัดการฝ่ายผลิตภัณฑ์ของ Turbo Aftermarket Services (AMS) สำหรับหน่วย Nikkiso Cryogenic Services (NCS)

การเพิ่มสมาชิกใหม่ให้ทีมผู้บริหารนี้จะช่วยสนับสนุนวัตถุประสงค์ของกลุ่มเพื่อขยาย AMS สำหรับ Turboexpanders ต่อไป กลุ่มผลิตภัณฑ์ Turbo All Brands จะขยายเพื่อรองรับและให้บริการแบรนด์ต่างๆ เพิ่มขึ้น รวมถึง ACD, Rotoflow, Atlas Copco และ Cryostar เป็นต้น

Etan สำเร็จการศึกษาระดับปริญญาด้านวิศวกรรมการบินและอวกาศจากมหาวิทยาลัยแคลิฟอร์เนีย (University of California) ซานดิเอโก เขาเริ่มประกอบอาชีพเป็นผู้ให้บริการบ่อน้ำมันแก่ลูกค้าในอุตสาหกรรมน้ำมันและก๊าซในรัฐเท็กซัส โดยทำงานให้กับ Schlumberger และ Baker Hughes ในปี 2017 เขาได้เข้าร่วม ACD LLC เป็นผู้จัดการการบริการภาคสนาม หลังจาก Nikkiso เข้าซื้อกิจการในปี 2019 เขาได้เปลี่ยนไปรับบทบาทผู้จัดการการบริการของ Turbo AMS สำหรับ NCS และได้ช่วยย้ายแผนก ACD Turbo AMS ไปยังโรงงานแห่งใหม่ในเออร์ไวน์ รัฐแคลิฟอร์เนีย เขาช่วยพัฒนามาตรฐานและกระบวนการขึ้นใหม่กับศูนย์บริการระหว่างประเทศสำหรับ Turbo AMS ในเออร์ไวน์ โครงสร้างใหม่ได้ช่วยให้การดำเนินธุรกิจระดับท้องถิ่นประสบความสำเร็จ และจะรับรองการสนับสนุนอย่างเหมาะสมสำหรับทีม Turbo AMS ทั่วโลก

“ทีม NCS รู้สึกตื่นเต้นที่ได้ Etan มาสวมบทบาทการจัดการผลิตภัณฑ์ Turbo AMS ใหม่นี้” Jim Estes ประธานของ NCS กล่าว “ประสบการณ์นานหลายปีและการมุ่งเน้นในการบริการลูกค้าของเขานั้นเกินกว่าที่เราคาดหวัง ผมหวังว่าจะได้เห็นเขาประสบความสำเร็จต่อไปในบทบาทใหม่นี้”

Nikkiso Cryogenic Services ให้บริการและการสนับสนุนทั่วโลก รวมถึงสำนักงานในมาเลเซีย เยอรมนี อินเดีย ออสเตรเลีย ไต้หวัน และจีน รวมถึงสำนักงานอีก 6 แห่งในอเมริกาเหนือ

เกี่ยวกับ CRYOGENIC INDUSTRIES
Cryogenic Industries, Inc. (ปัจจุบันเป็นสมาชิกของ Nikkiso Co., Ltd.) บริษัทสมาชิกผลิตอุปกรณ์แปรรูปก๊าซไครโอเจนทางวิศวกรรมและโรงงานที่มีกระบวนการขนาดเล็กสำหรับก๊าซธรรมชาติเหลว (LNG), บริการที่ดีและอุตสาหกรรมก๊าซสำหรับอุตสาหกรรม Cryogenic Industries ก่อตั้งขึ้นเมื่อ 50 ปีที่แล้ว เป็นบริษัทแม่ของ ACD, Cosmodyne และ Cryoquip และเป็นกลุ่มที่ควบคุมโดยทั่วไปซึ่งมีหน่วยงานปฏิบัติการประมาณ 20 แห่ง

สำหรับข้อมูลเพิ่มเติม โปรดไปที่ www.nikkisoCEIG.com และ www.nikkiso.com

ติดต่อด้านสื่อ:

Anna Quigley
+1.951.383.3314
aquigley@cryoind.com

Change intended to drive rapid digital transformation, leverage full scale of cloud-connected technology platforms, and accelerate growth of ResMed’s SaaS business

SAN DIEGO, Aug. 25, 2021 (GLOBE NEWSWIRE) — ResMed (NYSE: RMD, ASX: RMD), today announced the promotion of Bobby Ghoshal to President of ResMed’s SaaS business, effective immediately. Raj Sodhi will be leaving full-time employment at ResMed, effective September 1.

Bobby has over 25 years of experience across medical and technology industries, most currently serving as ResMed’s Chief Technology Officer (CTO), with strong experience building and leading high-performing teams to accelerate the adoption of digital platforms across enterprises. From February 2016 until April 2018, Bobby served as chief operating officer for Brightree, a ResMed-owned provider of cloud-based software-as-a-service for out-of-hospital care. ResMed will commence a search process for a new CTO immediately; Bobby will remain in the CTO role until a replacement is found.

“As we look ahead to 2025, we believe the future of healthcare is outside the hospital and we have an amazing mission to improve over 250 million lives,” said Mick Farrell, ResMed’s CEO. “We must accelerate our efforts to bring software technology, along with digital and commercial innovation, to these care settings. Digital solutions, scalable digital platforms, and software embedded into our customers’ workflows are critical to our growth strategy – Bobby’s experience as ResMed’s CTO, his hands-on experience with Brightree, and his strong background across many industries makes him the right leader to accelerate our SaaS business to meet our goals for 2025 and beyond.”

“I’d like to thank Raj for the incredible work he’s done over the past nine years at ResMed,” continued Farrell. “Raj played an important role in developing the healthcare informatics function at ResMed, a function that helped to transform the company on our path to becoming the leader in digital health. He also helped to craft the SaaS strategy and lead multiple acquisitions that established the foundation for us to scale and grow our SaaS business in home medical equipment, skilled nursing facilities, home health, hospice, private duty homecare, and beyond.”

About ResMed
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.

For investors	For media
Amy Wakeham	Jayme Rubenstein
+1 858.836.5000	+1 858.836.6798
investorrelations@resmed.com	news@resmed.com